Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Part of paid clinical trials in Omaha, Nebraska.

Sponsor
University of Rochester
Study ID
NCT00547534
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bortezomib — DRUG
    1.3 mg/m\^2 on days 1, 4, 8, 11
  • bendamustine — DRUG
    90 mg/m\^2 days 1 and 4
  • rituximab — DRUG
    375 mg/m\^2 day 1

Study Details

The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.

Key Dates

Start date
Oct 31, 2007
Status verified
Jul 2015
Primary completion
Jun 30, 2009
Completion
Oct 31, 2009

Study Design

Enrollment
31 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lymphoma Subjects receiving protocol therapy
    Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.

Primary Outcome Measure

Number of Participants With Progression Free Survival at 2 Years [ Time Frame: Two years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Nebraska Medical CenterOmahaNebraska68198-
Cornell Wiell Medical CollegeNew YorkNew York10021-
University of Rochester Medical Center (James P. Wilmot Cancer Center)RochesterNew York14642-

Find similar trials in Omaha, NE

By research site
Nebraska Medical Center· Omaha, NECornell Wiell Medical College· New York, NYUniversity of Rochester Medical Center (James P. Wilmot Cancer Center)· Rochester, NY

Related Studies